Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

20141,937 citationsJournal Articlebronze Open Access

Authors

Richard G. Langley · Dalhousie University

Boni E. Elewski · University of Alabama at Birmingham

Mark Lebwohl · Mount Sinai Hospital

Kristian Reich · Dermatologikum Hamburg

C.E.M. Griffiths · Manchester Academic Health Science Centre

Kim Papp · Clinical Research Management

L. Puig

Abstract

Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).

Topics & Keywords

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Autoimmune Bullous Skin Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 4, pp. 326-338

DOI: 10.1056/nejmoa1314258

Field-Weighted Citation Impact: 78.83